Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India

Back Stocks profile

Stock analysis tool for investors

Strides Pharma Science Ltd.

NSE: STAR | BSE:532531

₹936.45 -13.95 (-1.47%) 1D

Pharmaceuticals & Biotechnology

Buy Sell
View detailed Technical chart

Open an Account with Bigul in 5 minutes

Performance

Today’s low

931.00

Today’s High

964.80

52W low

412.10

52W High

993.80

Open Price

953.10

Prev. Close

879.6500

Volume

166438.00

Value

155860865.10

Fundamentals

Market Cap

8607.50

Price to Earnings

-121.90

Price to Book Value

4.20

Dividend Yield

0.20

PE to Growth

-1.90

Op Revenue TTM

4051.12

Net Profit TTM

-70.61

Cash From Operating Activity

701.06

Return on Equity %

-3.32

EMA & SMA

Bullish Moving Averages

10

Bearish Moving Averages

6

5Day EMA

944.9

10Day EMA

944.7

12Day EMA

943.2

20Day EMA

934

26Day EMA

926.3

50Day EMA

897.7

100Day EMA

839.3

200Day EMA

736

5Day SMA

945.7

10Day SMA

946.7

20Day SMA

943

30Day SMA

912.5

50Day SMA

894.2

100Day SMA

850.7

150Day SMA

778.2

200Day SMA

707.5

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

05 Jul, 2024

53.6

Week

55.5

Month

52

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

944.08

PIVOT

First Resistance

957.17

Second Resistance

977.88

Third Resistance

990.97

First Support

923.37

Second Support

910.28

Third Support

889.57

Relative Strength Index

53.79

Money Flow Index

59.92

MACD

16.94

MACD Signal

20.66

Average True Range

29.8

Average Directional Index

7.9

Rate of Change (21)

7.19

Rate of Change (125)

36.17

Commodity Channel Index

-1.5

Williams %R

-84

BETA

1 Month

0.9

3 Month

0.37

1 Year

0.37

3 Year

0.19

PRICE CHANGE ANALYSIS

↓ -0.53%

1 Week

Low

High

931

965

↑ 11.76%

1 Month

Low

High

833.1

993.85

↑ 13.13%

3 Months

Low

High

687.2

993.85

↑ 28.95%

6 Months

Low

High

643.8

993.85

↑ 93.64%

1 Year

Low

High

412.1

993.85

Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 647.27 528.70 562.63 486.97 589.93 416.27 501.71 430.65 540.49 447.06 597.41
Operating Expenses Qtr 526.84 454.36 497.02 419.76 444.12 340.91 486.77 484.22 437.82 435.92 528.03
Operating Profit Qtr 90.79 65.66 43.27 55.56 119.44 45.60 -5.53 -61.03 17.83 3.64 46.96
EBIDT Qtr Cr 120.35 69.05 65.61 67.21 130.81 75.36 14.94 -53.57 102.66 11.14 69.37
Depreciation Qtr 20.81 21.06 21.34 21.46 22.71 22.26 24.35 24.30 24.41 26.23 27.09
Net Profit Qtr 53.66 2.54 1.28 8.00 62.40 12.54 -4.00 -66.25 200.50 -17.60 18.52
Basic EPS Qtr 5.84 0.28 0.14 0.89 6.91 1.39 -0.44 -7.38 22.33 -1.96 2.06
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 2225.56 1938.56 2102.49 1946.56 1774.31
Operating Expenses Annual Cr 1897.98 1756.02 1902.37 1670.25 1464.11
Operating Profit Annual 255.28 98.48 76.63 187.32 210.04
Operating Profit Margin Annual % 11.47 5.08 3.64 9.62 11.84
Total Expenses Annual Cr 2150.58 1988.32 2080.98 1834.93 1622.45
EBIDT Annual Cr 327.58 182.54 200.12 276.32 310.20
EBIDT Annual margin % 14.72 9.42 9.52 14.20 17.48
Depreciation 84.67 93.62 104.37 99.34 91.63
PAT Before ExtraOrdinary Items Annual Cr 65.49 4.68 180.19 78.24 111.70
Net Profit Annual 65.49 4.68 180.19 78.24 111.70
Basic EPS Annual 7.20 0.52 20.08 8.73 12.47
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 3561.12 3455.05 3406.28 3248.06 3175.17
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 281.36 367.86 185.85 382.64 62.30
Total Current Liabilities Annual Cr 1995.30 1796.83 1841.32 1590.64 1437.79
Total Capital Plus Liabilities Annual Cr 5837.78 5619.74 5433.86 5221.33 4675.25
Fixed Assets Annual 650.20 651.94 672.62 755.16 724.48
Total Non Current Assets Annual 3421.93 3493.34 3458.61 3477.48 3218.45
Total Current Assets Annual 2415.86 2126.40 1975.25 1743.86 1456.80
Total Assets Annual 5837.78 5619.74 5433.86 5221.33 4675.25
Contingent Liabilities plus Commitments Annual Cr - 632.08 2345.08 1929.34 3498.11
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual -35.76 241.74 -282.69 282.76 148.84
Cash from Investing Activity Annual -61.27 -182.58 18.78 -275.64 50.88
Cash from Financing Annual Activity 107.62 10.82 250.73 -48.64 -203.56
Net Cash Flow Annual - 69.98 -13.18 -41.52 -3.84
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 387.50 382.61 379.36 362.18 354.51
ROE Annual % 1.83 0.13 5.28 2.40 3.51
ROCE Annual % 6.32 2.32 2.66 4.87 6.75
Total Debt to Total Equity Annual 0.45 0.39 0.37 0.26 0.27
EBDIT Annual Margin % 15.21 9.84 10.11 14.87 18.52
Indicator Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021 Graph
Total Qtr Revenue cr 1070.49 1046.42 1035.28 938.64 1013.49 891.05 920.56 953.62 952.08 804.58 743.68
Operating Expenses Qtr 854.30 843.86 846.30 763.40 830.81 748.50 798.97 879.92 823.85 792.86 735.04
Operating Profit Qtr 229.73 193.81 153.13 166.59 155.56 116.34 98.13 60.15 42.16 1.53 -13.57
EBIDT Qtr Cr 208.19 246.65 24.05 169.26 175.34 184.10 154.68 7.93 51.27 -3.71 -51.26
Depreciation Qtr 49.76 51.23 60.10 59.59 60.93 60.22 61.70 60.40 60.68 60.90 56.56
Net Profit Qtr 18.18 49.67 -131.34 -7.11 -9.54 -80.03 22.82 -135.89 29.22 -121.67 -162.56
Basic EPS Qtr 1.98 5.43 -14.54 -0.79 -1.06 -8.86 2.54 -15.13 3.25 -13.55 -18.12
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 4090.82 3778.72 3202.24 3367.30 2805.08
Operating Expenses Annual Cr 3307.86 3258.21 3090.36 2681.04 2236.07
Operating Profit Annual 743.26 430.18 -20.11 634.83 515.90
Operating Profit Margin Annual % 18.17 11.38 -0.63 18.85 18.39
Total Expenses Annual Cr 3842.99 3762.60 3500.11 3037.39 2565.49
EBIDT Annual Cr 782.97 520.51 111.88 686.26 569.01
EBIDT Annual margin % 19.14 13.77 3.49 20.38 20.28
Depreciation 220.68 243.25 233.01 206.29 173.70
PAT Before ExtraOrdinary Items Annual Cr 27.20 54.38 -363.44 341.61 150.59
Net Profit Annual -70.61 -202.63 -460.21 268.44 36.39
Basic EPS Annual -7.76 -22.49 -51.28 29.96 5.68
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 2125.56 2195.16 2358.82 2776.66 2527.42
Minority Interest Liability Annual Cr -53.86 -39.38 24.09 37.34 67.24
Total Non Current Liabilities Annual Cr 888.79 1475.34 1180.87 1462.67 1012.22
Total Current Liabilities Annual Cr 2879.26 2990.20 3411.68 2738.35 2544.86
Total Capital Plus Liabilities Annual Cr 5839.76 6638.42 6975.86 7015.02 6151.73
Fixed Assets Annual 1497.56 1948.22 2151.80 2186.19 2083.04
Total Non Current Assets Annual 2870.76 3395.06 3614.03 4197.79 3779.62
Total Current Assets Annual 2969.00 3243.36 3361.83 2817.23 2372.11
Total Assets Annual 5839.76 6638.42 6975.86 7015.02 6151.73
Contingent Liabilities plus Commitments Annual Cr - 660.45 1211.57 891.63 2425.54
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 701.07 44.41 -257.81 481.44 204.79
Cash from Investing Activity Annual -150.25 302.47 -118.73 -520.82 1306.16
Cash from Financing Annual Activity -693.32 -213.92 421.32 -15.80 -1709.45
Net Cash Flow Annual - 132.96 44.77 -55.18 -198.50
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 225.43 238.73 265.39 313.78 289.69
ROE Annual % -3.32 -9.23 -19.51 9.66 1.43
ROCE Annual % 18.99 7.59 -3.39 11.22 10.95
Total Debt to Total Equity Annual 1.14 1.26 1.18 0.69 0.73
EBDIT Annual Margin % 19.32 14.11 3.64 20.69 20.67
Name Holding Percent Holding Id Pledged % Locked %
ADITYA BIRLA SUN LIFE TRUSTEE 5.03 75067619 - -
AMANSA HOLDINGS PRIVATE LIMITED 4.15 75067629 - -
MORGAN STANLEY ASIA (SINGAPORE) PTE. - ODI 1.08 75067632 - -
MUKUL MAHAVIR AGRAWAL 1.63 75067639 - -
SATPAL KHATTAR 1.7 75067641 - -
Name Holding Percent Holding Id Pledged % Locked %
ARUN KUMAR PILLAI 2.11 75067590 78.46 0
K R RAVISHANKAR 1.37 75067591 0 0
PRONOMZ VENTURES LLP 17.18 75067604 91.67 0
KARUNA BUSINESS SOLUTIONS LLP 3.51 75067605 37.77 62.01
Name Holding Percent Holding Id
QUANT MUTUAL FUND 5.42 75067618
ADITYA BIRLA SUN LIFE TRUSTEE 5.03 75067619
ROUTE ONE OFFSHORE MASTER FUND, L.P. 5.06 75067628
AMANSA HOLDINGS PRIVATE LIMITED 4.15 75067629
ROUTE ONE FUND I, L.P. 2.17 75067630
BNP PARIBAS FINANCIAL MARKETS 1.16 75067631
MORGAN STANLEY ASIA (SINGAPORE) PTE. - ODI 1.08 75067632
LIFE INSURANCE CORPORATION OF INDIA 3.17 75067621
MAX LIFE INSURANCE COMPANY LIMITED 1.64 75067622
OMAN INDIA JOINT INVESTMENT FUND II 1.1 75067624
Name Holding Percent Holding Id
MUKUL MAHAVIR AGRAWAL 1.63 75067639
SATPAL KHATTAR 1.7 75067641
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Aug 04, 2023 1.5 FINAL Aug 04, 2023 Equity Share
Aug 05, 2021 2.5 FINAL Aug 06, 2021 Equity Share
Jul 24, 2020 2 FINAL Jul 27, 2020 Equity Share
Aug 22, 2019 12 INTERIM Aug 23, 2019 Equity Share
Jul 19, 2019 3 FINAL - Equity Share
Sep 12, 2018 2 FINAL - Equity Share
Sep 07, 2017 4.5 FINAL - Equity Share
Jul 21, 2016 4 FINAL - Equity Share
Jul 22, 2015 3 FINAL - Equity Share
Oct 16, 2014 105 SPECIAL Oct 17, 2014 Equity Share
Sep 01, 2014 5 FINAL - Equity Share
Dec 19, 2013 500 SPECIAL Dec 20, 2013 Equity Share
May 30, 2013 2 FINAL - Equity Share
May 14, 2012 2 FINAL - Equity Share
May 18, 2011 1.5 FINAL - Equity Share
May 21, 2010 1.5 FINAL - Equity Share
Jun 12, 2007 2 FINAL - Equity Share
Jun 06, 2006 2 FINAL - Equity Share
Jun 13, 2005 1.5 FINAL - Equity Share
Ex-Date Split Ratio Record Date
Ex-Date Purpose Notes
May 22, 2024 Audited Results & Final Dividend -
Jan 30, 2024 Quarterly Results -
Oct 30, 2023 Quarterly Results -
Sep 25, 2023 Scheme of Arrangement -
Aug 02, 2023 Quarterly Results -
May 25, 2023 Audited Results & Final Dividend -
Jan 24, 2023 Quarterly Results -
Nov 14, 2022 Quarterly Results -
Jul 29, 2022 Quarterly Results -
Jul 25, 2022 Others Inter alia, to consider and approve Intimation of raising of funds by way of issuance of Non-Convertible Debentures under Regulation 29 of SEBI Listing Regulations.
May 24, 2022 Audited Results & Dividend -
Feb 10, 2022 Quarterly Results & Others To consider Fund Raising (Revised)
Nov 10, 2021 Quarterly Results -
Aug 06, 2021 Quarterly Results -
May 27, 2021 Audited Results -
Feb 04, 2021 Quarterly Results -
Oct 29, 2020 Quarterly Results -
Aug 05, 2020 Quarterly Results -
May 20, 2020 Audited Results & Dividend -
Jan 30, 2020 Quarterly Results -
Oct 25, 2019 Others -
Jul 29, 2019 Quarterly Results & Interim Dividend -
May 10, 2019 Audited Results & Dividend -
Jan 29, 2019 Quarterly Results -
Oct 31, 2018 Quarterly Results -
Aug 08, 2018 Quarterly Results -
May 18, 2018 Audited Results & Dividend -
Feb 09, 2018 Quarterly Results -
Oct 31, 2017 Quarterly Results -
Aug 11, 2017 Quarterly Results -
May 18, 2017 Audited Results & Dividend -
Feb 03, 2017 Quarterly Results -
Oct 28, 2016 Quarterly Results -
Aug 17, 2016 Quarterly Results -
May 16, 2016 Audited Results & Dividend -
Feb 08, 2016 Quarterly Results -
Oct 27, 2015 Quarterly Results -
Jul 30, 2015 Quarterly Results -
May 22, 2015 Audited Results & Dividend Allotted 10,000 fully paid equity shares of Rs.10/- each under the Strides Arcolab ESOP 2011 Scheme of the Company.
Feb 02, 2015 Quarterly Results -
Nov 07, 2014 Quarterly Results -
Oct 07, 2014 Special Dividend -
Jul 25, 2014 Quarterly Results -
May 23, 2014 Audited Results & Dividend -
Feb 07, 2014 Quarterly Results -
Dec 10, 2013 Special Dividend -
Nov 14, 2013 Quarterly Results -
Jul 25, 2013 Quarterly Results -
Apr 25, 2013 Quarterly Results -
Feb 28, 2013 Audited Results & Dividend -
Oct 19, 2012 Quarterly Results -
Jul 27, 2012 Quarterly Results -
Apr 26, 2012 Quarterly Results -
Feb 27, 2012 Audited Results & Dividend -
Oct 24, 2011 Quarterly Results -
Jul 27, 2011 Quarterly Results -
Apr 25, 2011 Quarterly Results -
Feb 24, 2011 Audited Results & Dividend -
Oct 27, 2010 Quarterly Results -
Jul 27, 2010 Quarterly Results -
Apr 22, 2010 Quarterly Results -
Feb 24, 2010 Audited Results & Dividend -
Oct 30, 2009 Quarterly Results -
Jul 30, 2009 Quarterly Results -
Apr 24, 2009 Quarterly Results -
Apr 13, 2009 Others inter alia, to consider various options of reorganizing the business of the Company and its Subsidiary Companies.
Feb 25, 2009 Audited Results & Dividend -
Oct 31, 2008 Quarterly Results -
Jul 22, 2008 To consider the proposal of Merger inter alia, to Consider the proposal to merge Grandix Pharmaceuticals Ltd, Grandix Laboratories Ltd and Global Remedies (all subsidiaries of the Company) with the Company.
Apr 28, 2008 Quarterly Results -
Mar 07, 2008 Audited Results & Dividend -
Oct 30, 2007 Quarterly Results -
Jul 27, 2007 Quarterly Results -
Apr 26, 2007 Quarterly Results -
Jan 29, 2007 Accounts & Dividend -
Oct 27, 2006 Quarterly Results -
Jul 26, 2006 Quarterly Results -
Apr 25, 2006 Quarterly Results -
Mar 01, 2006 General -
Feb 09, 2006 Accounts, Dividend & ESOP -
Dec 21, 2005 Appointment of Directors -
Oct 27, 2005 Quarterly Results -
Jul 29, 2005 Quarterly Results -
Jun 01, 2005 Acquisition To consider acquiring a majority stake in Biopharma, a Venezuelean marketing company subject to due diligence.
Apr 25, 2005 Quarterly Results -
Apr 12, 2005 To consider raising of funds To consider the proposal for raising of funds up to an amount not exceeding Rs 550 million through issue of Cumulative Redeemable Preference Shares (CRPS).
Mar 25, 2005 Accounts, Dividend & Others Voluntary Delisting of Shares from the Bangalore Stock Exchange Ltd & Mangalore Stock Exchange.
Feb 04, 2005 Others To Consider a proposal for issue of foreign currency convertible bonds or such other similar securities to fund the proposed expansion of capacities.
Oct 29, 2004 Quarterly Results -
Oct 08, 2004 Others Preferential Offer
Jul 21, 2004 Quarterly Results -
Apr 21, 2004 Half Yearly Results -
Jan 19, 2004 Quarterly Results & Others To fix the date,time and venue for holding of an Extra ordianry General Meeting of the Company
Sep 04, 2003 Others A proposal for introduction of 'Employee Stock Option Plan 2003" and other related/incidental matters required to implement the same would be considered.
Apr 30, 2003 Half Yearly Results -
Ex-Date Bonus Ratio Record Date
Bigul
28 Jun 2024

Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015- Iftakhar Ahmed
Bigul
27 Jun 2024

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Copy of Newspaper publication for postal ballot notice
Bigul
26 Jun 2024

Strides Pharma Science Ltd - 532531 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 Intimation about launch of postal ballot to seek shareholders approval for appointment of Independent Director, Managing Director and Group CEO and Executive Director
Bigul
25 Jun 2024

Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Issuance of LOC - Inderpreet
Bigul
19 Jun 2024

Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation under Regulation 39(3) of SEBI(Listing Obligation and Disclosure Requirements) Regulation, 2015 - Vibhishanan V
Bigul
19 Jun 2024

Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Bigul
14 Jun 2024

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Retirement

 Intimation under Regulation 30 for completion of tenure of Mr. Bharat Shah as Independent Director of the Company
Bigul
29 May 2024

Strides Pharma Science Ltd - 532531 - Compliances-Reg.24(A)-Annual Secretarial Compliance

 Annual Secretarial Compliance Report for the year ended March 31, 2024
28 May 2024

Strides Pharma Q4 Results Review - Traction In U.S. Building Up: ICICI Securities

 gSuprep launch in U.S. and traction in emerging markets drives beat in margin
Bigul
27 May 2024

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Transcript of Earnings Call held on May 22, 2024
See all News

FAQs

The latest market price of Strides Pharma Science Ltd. on NSE was Rs. 936.45 as of today.

The opening share price of Strides Pharma Science Ltd. was Rs. 953.10 as of today.

The 52-week high share price of Strides Pharma Science Ltd. was Rs. 993.80.

The 52 week low share price of Strides Pharma Science Ltd. was Rs. 412.10.

Please find Corporate actions section for more details.

The PE ratio of Strides Pharma Science Ltd. is -1.90. Please refer to the Fundamentals section for further details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

The latest dividend declared by Strides Pharma Science Ltd. was on 2023-08-04 for Rs. 1.5 per share. According to today’s share price, the dividend yield of Strides Pharma Science Ltd. stands at 0.20. Please refer to the Corporate Actions section for further details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Strides Pharma Science Ltd..

Close

Let's Open Free Demat Account